Japan thumps Pfizer for missing 200 side effect reports; Caraco should have warned plant workers of job loss, court says;

@FiercePharma: Academic docs and biotechs partner with veterinarians to find cancer cures. More from FierceAnimalHealth | Follow @FiercePharma

@CarlyHFierce: Can Sprout's Addyi shrug off serious side effects? These blockbusters did. FiercePharmaMarketing article | Follow @CarlyHFierce

> Pfizer ($PFE) is under fire at Japan's health ministry, which says the U.S.-based multinational failed to report about 200 cases of serious side effects, including 6 deaths, over a 6-year period ending in 2014. Report

> Caraco Pharmaceutical, a U.S. subsidiary of India's Sun Pharma, was still required to give notice to production workers that they'd be laid off, even after the manufacturer was raided by U.S. regulators, a court found. Report

> India's Dr. Reddy's Laboratories ($RDY) is reshuffling its top management after the departure of its North American chief, Umang Vora. Report

> South Africa-based Adcock Ingram plans to sell off an underperforming Indian unit, Cosme Farm Laboratories, after two years of writedowns. Report

> Slovenia-based drugmaker Krka saw profits climb 5% for the second quarter as strong sales in Western Europe made up for weaker performance in Russia. Report

> Two workers at a Gedeon Richter plant in Budapest were injured in an explosion. Report

Medical Device News

@FierceMedDev: Israeli nitric oxide drug-device player files for up to $36M Nasdaq IPO. Article | Follow @FierceMedDev

@VarunSaxena2: Providence Medical receives $12M in financing to expand sales of its spinal fusion devices. Story | Follow @VarunSaxena2

@EmilyWFierce: Recipharm strikes development deal for RedHill's bacteria-fighter candidate. FierceCRO item | Follow @EmilyWFierce

> Greatbatch grabs Lake Regional Medical for $730M to expand surgical offerings. News

> Abbott denies FT report that it's preparing $25B bid for St. Jude Medical. Article

Biotech News

@FierceBiotech: UCSF cardiology chief builds a case for two new targets for heart drugs. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: I'm happy to see $MDVN back in a late-stage development race. It's been awhile, and they're smart, aggressive players. More from FiercePharmaMarketing | Follow @JohnCFierce

> J&J positions blockbuster contender daratumumab for a multiple myeloma showdown. Report

> Repatha OK looming, analysts wait to see if Amgen will start PCSK9 price war. More

> Novo Nordisk defers dream of expanding Victoza label after PhIII falls short. Story

> MorphoSys trades assets with Immatics to bolster I-O ambitions. Article

Vaccines News

> Pfizer's Trumenba shows 'robust' MenB protection in two PhIII trials. News

> Valneva licenses EB66 technology to develop human, veterinary vaccines. Report

> Takeda expands vaccine platform rights with Nanotherapeutics agreement. More

> FluGen reels in $12M to fund PhI of its universal flu jab. Story

> Scripps Research Institute, J&J test 'universal' flu vaccine in mice, monkeys. Article

CRO News

> WuXi inks lab testing pact with Chinese Lee's Pharm. News

> Germany lists 54 GVK suspensions as EU comes down on Indian CRO. More

> Recipharm strikes development deal for RedHill's bacteria-fighter candidate. Report

> CRO field to grow nearly 10% annually through 2019, report says. Story

> India's Accutest Research Labs expands into Latin America. Article

Pharma Manufacturing News

> Shire works deal with Sanquin so it can boost production of rare disease drug. More

> Woodcock says FDA will keep new plant quality grades a secret. Report

> Sterilization specialist on expansion streak. Item

> Sucampo gets control of Amitiza production in deal for Japanese company. Story

> Novo picks Clayton, NC, for its first U.S. API plant. Article

Pharma Asia News

> India's Gujarat state moves closer to country's first medical device testing lab. Story

> China's Shenzhen Hepalink keeps N. American deal stream rolling with Cytovance. More

> Oncology trials in China may see pilot program for 60-day IND decision. Story

> BD Life Science buys Silicon Valley-based Cellular Research, part of Decheng portfolio. Article

> Japan's PAFSC to review application from Takeda on glatiramer this week. Item

And Finally... Johnson & Johnson ($JNJ) sold off its Splenda brand sweetener as part of its ongoing strategy to focus in on key consumer health product lines. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.